Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with prophylactic platelet transfusions with standard‐dose schedule (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with prophylactic platelet transfusions with standard‐dose schedule (low certainty).
1 finding from 1 review
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with high‐dose schedule (moderate certainty).
1 finding from 1 review
Number of days on which bleeding occurred per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Day time asthma score Standardised mean difference · Preschool children (<6 years)
1 finding from 1 review
Day time asthma score Mean difference · School‐aged children and adults
1 finding from 1 review
Maternal death · women during pregnancy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Maternal death · women during pregnancy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Intervention not reported
Number of days sick in bed · children and adults in low‐ and middle‐income countries
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of days sick in bed Z‐score of number ( · children and adults in low‐ and middle‐income countries
1 finding from 1 review
Proportion of individuals tested (12 days to 8 weeks of · Sexually active people
1 finding from 1 review
Treatment failure at day 28 · adults and children with uncomplicated P falciparum malaria
Artemisinin‐naphthoquine showed no clear difference in treatment failure at day 28 compared with AL (low certainty).
1 finding from 1 review
Treatment failure at day 42 · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether artemisinin‐naphthoquine changes treatment failure at day 42 compared with AL (very low certainty).
1 finding from 1 review
Treatment failure at day 28 · adults and children with uncomplicated P falciparum malaria
1 finding from 1 review
Treatment failure at day 42 · adults and children with uncomplicated P falciparum malaria
It is very uncertain whether artemisinin‐naphthoquine changes treatment failure at day 42 compared with DHA‐P (very low certainty).
1 finding from 1 review
Headache (frequency) · patients with tension‐type headache
1 finding from 1 review
Headache (frequency) · patients with tension‐type headache
1 finding from 1 review
Length of hospitalisation (days) · exacerbations of COPD
1 finding from 1 review